PRURISOL: The Phase 2 study will consist of a significant number of patients across multiple centers," commented Leo Ehrlich, CEO at Cellceutix. "Our intentions are to pursue a CE mark in Europe at the same time as applying for clearance in the United States, so we are exploring some clinical sites overseas as well to host a portion of the trials. We want to broaden our footprint globally with Prurisol? should the trials go as we anticipate, so we are working at full speed to make this a successful project in an attempt to receive approval as expeditiously as possible."